Nasdaq: BRVE/Biotechnology

Braveheart Bio, Inc.

San Francisco, CA, United States

Company overview

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.